Insider Trading Alert - GPS, HCN And LGND Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, July 1, 2014, 44 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $700.00 to $89,120,000.00.

Highlighted Stocks Traded by Insiders:

Gap (GPS) - FREE Research Report

Keiser John T., who is EVP Global Product Ops at Gap, sold 18,171 shares at $41.39 on July 1, 2014. Following this transaction, the EVP Global Product Ops owned 11,955 shares meaning that the stake was reduced by 60.32% with the 18,171-share transaction.

The shares most recently traded at $41.68, up $0.29, or 0.7% since the insider transaction. Historical insider transactions for Gap go as follows:

  • 4-Week # shares sold: 520,785
  • 12-Week # shares sold: 582,785
  • 24-Week # shares sold: 582,785

The average volume for Gap has been 3.9 million shares per day over the past 30 days. Gap has a market cap of $18.3 billion and is part of the services sector and retail industry. Shares are up 6.6% year-to-date as of the close of trading on Tuesday.

The Gap, Inc. operates as an apparel retail company worldwide. It provides apparel, accessories, and personal care products for men, women, and children under the Gap, Banana Republic, Old Navy, Piperlime, Athleta, and Intermix brands. The stock currently has a dividend yield of 2.12%. The company has a P/E ratio of 15.9. Currently, there are 9 analysts who rate Gap a buy, no analysts rate it a sell, and 17 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GPS - FREE

TheStreet Quant Ratings rates Gap as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Gap Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Health Care REIT (HCN) - FREE Research Report

Estes Scott A, who is EVP and CFO at Health Care REIT, sold 8,616 shares at $62.68 on July 1, 2014. Following this transaction, the EVP and CFO owned 88,413 shares meaning that the stake was reduced by 8.88% with the 8,616-share transaction.

The shares most recently traded at $62.07, down $0.61, or 0.99% since the insider transaction. Historical insider transactions for Health Care REIT go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 150
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 4,825
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 4,825

The average volume for Health Care REIT has been 2.2 million shares per day over the past 30 days. Health Care REIT has a market cap of $18.3 billion and is part of the financial sector and real estate industry. Shares are up 17.72% year-to-date as of the close of trading on Tuesday.

Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The stock currently has a dividend yield of 5.07%. The company has a P/E ratio of 164.9. Currently, there are 6 analysts who rate Health Care REIT a buy, 2 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCN - FREE

TheStreet Quant Ratings rates Health Care REIT as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Health Care REIT Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ligand Pharmaceuticals (LGND) - FREE Research Report

Foehr Matthew W, who is EVP and COO at Ligand Pharmaceuticals, bought 428 shares at $43.79 on July 1, 2014. Following this transaction, the EVP and COO owned 53,885 shares meaning that the stake was boosted by 0.8% with the 428-share transaction.

Berkman Charles S, who is VP, Gen. Counsel & Secretary at Ligand Pharmaceuticals, bought 329 shares at $43.79 on July 1, 2014. Following this transaction, the VP, Gen. Counsel & Secretary owned 27,307 shares meaning that the stake was boosted by 1.22% with the 329-share transaction.

Herman Melanie J, who is Director of Accounting at Ligand Pharmaceuticals, bought 98 shares at $43.79 on July 1, 2014. Following this transaction, the Director of Accounting owned 2,728 shares meaning that the stake was boosted by 3.73% with the 98-share transaction.

The shares most recently traded at $64.62, up $20.83, or 32.23% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:

  • 4-Week # shares bought: 293
  • 4-Week # shares sold: 4,667
  • 12-Week # shares bought: 293
  • 12-Week # shares sold: 4,667
  • 24-Week # shares bought: 293
  • 24-Week # shares sold: 18,167

The average volume for Ligand Pharmaceuticals has been 278,800 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 20.76% year-to-date as of the close of trading on Tuesday.

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. The company has a P/E ratio of 132.5. Currently, there are 5 analysts who rate Ligand Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGND - FREE

TheStreet Quant Ratings rates Ligand Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Ligand Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices